TGF-β / Smad Signaling
The TGF-β family is generally classified into two sub-families, TGF-β ligands, and bone morphogenic protein (BMP) ligands. In canonical signaling, receptor activation lead to phosphorylation of a group of transcription factors called Smads. TGF-β ligands bind to type II receptors (TGF-β II) which recruit and phosphorylate type I receptor (TGF-β I) on serine/threonine residues. The TGF-β I then recruits and phosphorylates a receptor regulated Smad (R-Smad). The R-Smad binds to the common Smad (Co-Smad) and forms a heterodimeric complex. This complex then translocates into the cell nucleus where it binds with nuclear co-factors to regulate the transcription of various target genes. Dysregulation of TGF-β/Smad signaling pathway is associated with a number of pathological conditions including fibrosis, cancer, immunodeficiency, diabetes and cardiovascular diseases etc.
-
B1287 Ro 31-8220Target: PKCSummary: pan-PKC inhibitor
-
B2191 Dequalinium ChlorideTarget: PKC|Calcium-Activated Potassium (KCa) ChannelsSummary: anti-tumor agent and PKC inhibitor
-
B2287 LY3649471 CitationSummary: inhibitor of TGF-β type I receptor kinase domain
-
B2288 PirfenidoneSummary: TGF-β production inhibitor
-
B3392 GSK269962ATarget: ROCK|RSK|MSKSummary: ROCK inhibitor
-
A8830 ZIP (SCRAMBLED)Summary: PKMζ inhibitor
-
B3709 Midostaurin (PKC412)Target: PKC|PKA|KDR|Flk1|PPK|c-Syk|CDK1/CyclinBSummary: PKC inhibitor
-
A3008 Y-27632 dihydrochloride19 CitationTarget: ROCKSummary: ROCK1 inhibitor
-
A2600 (-)-Epigallocatechin gallate (EGCG)Target: BACESummary: Antioxidant, antiangiogenic and antitumor agent
-
B7807 Netarsudil (AR-13324)Target: ROCKSummary: ROCK inhibitor